Attached files

file filename
EX-10.64 - SEPTEMBER 2016 AMENDMENT TO COMMERCIAL LINE OF CREDIT AGREEMENT AND NOTE - Adamis Pharmaceuticals Corpex10-64.htm
EX-32.2 - CERTIFICATION BY CFO - Adamis Pharmaceuticals Corpex32-2.htm
EX-32.1 - CERTIFICATION BY CEO - Adamis Pharmaceuticals Corpex32-1.htm
EX-31.2 - CERTIFICATION BY CFO - Adamis Pharmaceuticals Corpex31-2.htm
EX-31.1 - CERTIFICATION BY CEO - Adamis Pharmaceuticals Corpex31-1.htm
EX-23.2 - CONSENT OF HUDSON CISNE & CO., LLP - Adamis Pharmaceuticals Corpex23-2.htm
EX-23.1 - CONSENT OF MAYER HOFFMAN MCCANN P.C. - Adamis Pharmaceuticals Corpex23-1.htm
EX-21.1 - SUBSIDIARIES - Adamis Pharmaceuticals Corpex21-1.htm
EX-10.84 - MARCH 2017 AMENDED AND RESTATED LINE OF CREDIT PROMISSORY NOTE - Adamis Pharmaceuticals Corpex10-84.htm
EX-10.83 - EXECUTIVE EMPLOYMENT AGREEMENT - Adamis Pharmaceuticals Corpex10-83.htm
EX-10.81 - EXECUTIVE EMPLOYMENT AGREEMENT - Adamis Pharmaceuticals Corpex10-81.htm
EX-10.80 - BONUS PLAN - Adamis Pharmaceuticals Corpex10-80.htm
EX-10.65 - LOAN RELEASE AGREEMENT DATED AS OF NOVEMBER 14, 2016 - Adamis Pharmaceuticals Corpex10-65.htm
EX-10.63 - AMENDMENT TO LOAN AGREEMENT - Adamis Pharmaceuticals Corpex10-63.htm
EX-10.62 - SEPTEMBER 2016 LOAN AMENDMENT AND CONSOLIDATION AGREEMENT AMONG BEAR STATE BANK, - Adamis Pharmaceuticals Corpex10-62.htm
EX-10.61 - LOAN AMENDMENT AND ASSUMPTION AGREEMENT DATED AS OF NOVEMBER 3, 2016 - Adamis Pharmaceuticals Corpex10-61.htm
EX-10.4 - RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND AWARD AGREEMENT - Adamis Pharmaceuticals Corpex10-4.htm
10-K - ANNUAL REPORT - Adamis Pharmaceuticals Corpadmp_10k-123116.htm
 

ADAMIS PHARMACEUTICALS CORPORATION 10-K

 

 

Exhibit 10.85

 

Loan No. 5000279900

 

MARCH 2017 AMENDMENT TO LOAN AND SECURITY AGREEMENT

 

THIS MARCH 2017 AMENDMENT TO LOAN AND SECURITY AGREEMENT (the “March 2017 Amendment”) is entered into this ___ day of March, 2017, with an effective date of March 31, 2017, by and between BEAR STATE BANK, N.A., a national banking association (“Lender”), and ADAMIS PHARMACEUTICALS CORPORATION, a Delaware corporation (“Borrower”).

 

WHEREAS, Lender extended a business loan to Borrower, in the initial amount of Two Million and No/100 United States Dollars ($2,000,000.00) (the “Loan”), as set forth in that certain Loan and Security Agreement by and between Lender and Borrower dated March 2016 (collectively, with all previous amendments thereto, including without limitation, that certain Amendment to Loan and Security Agreement dated November 3, 2016, the “Loan Agreement”); and

 

WHEREAS, Borrower and Lender desire the Loan Agreement be amended as set forth in this March 2017 Amendment, but that all other terms, conditions, and provisions of the Loan Agreement remain in full force and effect solely except as set forth in this March 2017 Amendment;

 

WHEREAS, Borrower hereby intends to and by execution hereof ratifies and affirms Borrower’s unqualified and unconditional liability on all indebtedness of the Loan;

 

NOW, THEREFORE, for and in consideration of Lender’s agreement to the amendments set forth in this March 2017 Amendment, the Loan Agreement, and the covenants, warranties and representations of Borrower contained herein, Ten Dollars ($10.00) and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by all parties, it is agreed as follows:

 

AGREEMENTS

 

The recitals set forth above are not mere recitals of fact but are contractual in nature and are intended by the parties to be incorporated into this March 2017 Amendment by reference, except in the event of a conflict between the incorporated recitals and the numbered sections of this March 2017 Amendment, the numbered sections of this March 2017 Amendment shall control. Terms and provisions which are not otherwise defined herein shall have the same meanings as set forth in the Loan Agreement.

 

1.       Definitions. The following definitions, as set forth below, shall replace the definitions previously set forth in the Loan Agreement:

 

  (a)         “Collateral” collectively means:

 

(i)       The following Instruments:

 

(A)      that certain Promissory Note dated March 28, 2016, from U.S. Compounding, Inc., an Arkansas corporation (“USC”), in favor of Borrower, in the principal amount of up to Two Million and No/100 United States Dollars ($2,000,000.00) (the “USC Note”);

 

 

 

 

 

  (B)      that certain Certificate of Deposit No. 3000028062 of Borrower (the “CD”);

 

(ii)        All Accounts of Borrower currently or hereafter existing relating to Borrower’s rights under the USC Note; and all rights now or hereafter existing in and to all security agreements and other documents securing or otherwise relating to any such Accounts (collectively, the “Accounts”); and all General Intangibles or Payment Intangibles currently or hereafter existing relating to Borrower’s rights under the USC Note;

 

(iii)       Any and all substitutions and replacements therefor, and all product and proceeds of any and all of the foregoing Collateral and, to the extent not otherwise included; and

 

(iv)       All deeds of trust, mortgages or other instruments of debt, pledge or hypothecation evidencing or securing the USC Note, if any.

 

2.       Extension of Maturity of Loan. Borrower and Lender agree the Maturity Date of the indebtedness evidenced by the Loan Agreement and the other documents evidencing and securing the Loan, shall be March 1, 2018, as full set forth in that certain March 2017 Amended and Restated Line of Credit Promissory Note [Closed End Multiple Advance Note] executed of even date herewith (the “March 2017 Note”).

 

3.       Estoppel; Waiver; Ratification and Release.  For and in consideration of the maturity extension granted by Lender herein, Ten United States Dollars ($10.00) and other good and valuable consideration, receipt and sufficiency being acknowledged, Borrower, as evidenced by its signature below, agrees and acknowledges its unqualified and unconditional obligation for the Indebtedness without defense, affirmative defense, counterclaim, right of setoff or other impediment to collection, and the same, if existing, being expressly released and waived by Borrower in consideration for Lender entering into this March 2017 Amendment. 

 

4.       UCC. Notwithstanding any provisions hereof or execution by Lender, this March 2017 Amendment (and all documents executed in connection herewith) shall be voidable at the option of Lender should any lien searches or other confirmatory title information regarding the Collateral (to be provided at the expense of Borrower) reflect any default under the Loan or creation of any adverse claim or interest regarding the Collateral. In addition, Borrower authorizes Lender to file any and all initial, amendatory or continuation Uniform Commercial Code filings deemed necessary by Lender.

 

2 

 

 

5.        Good Standing of Borrower. Notwithstanding any provisions hereof or execution by Lender, this March 2017 Amendment (and all documents executed in connection herewith) shall be voidable at the option of Lender in the event Borrower is not validly existing and under its state of formation at the time of execution of this March 2017 Amendment.

 

6.         No Further Modifications. Except as expressly set forth above, the terms and provisions of the Loan Agreement shall remain in full force and effect.

 

[ Signatures appear on following page.]

 

3 

 

 

IN WITNESS WHEREOF, the parties hereto have duly executed this March 2017 Amendment this ___ day of March, 2017, with an effective date of March 31, 2017.

   
  BORROWER:
   
  ADAMIS PHARMACEUTICALS CORPORATION,
  a Delaware corporation
   
  By:  /s/ Robert O. Hopkins
  Name: ROBERT O. HOPKINS
  Title: CFO
   
  LENDER:
   
  BEAR STATE BANK, N.A.
  a national banking association
   
  By:  /S/ Steve Moore
  Name: STEVE MOORE
  Title: Executive Vice President

 

4